Enanta Pharmaceuticals Inc (ENTA)

[vinmantoo]

The Chinese company said that in antiviral cellular assays with infectious SARS-CoV-2, ASC11 showed much higher potency against the virus than other 3CLpro inhibitors including nirmatrelvir, Shionogi's (OTCPK:SGIOF) (OTCPK:SGIOY) oral drug S-217622, Pardes Biosciences' (PRDS) oral therapy PBI-0451, and Enanta Pharmaceuticals' (ENTA) oral medicine EDP-235.

Looks like China is still pushing treatments originating in China in their ultraNationalism fervor driven by Xi rather than taking steps to protect its citizens.

The goal of the phase 1 trial, which is expected to be completed within Q1 2023, is to identify a safe and efficacious dose for the pivotal phase 2/3 in patients with COVID-19.

In addition, the phase 1 study will determine if ASC11 needs to be boosted by ritonavir or not.

So they claim it is much more potent than EDP-235 but they don't know if it needs ritonavir. The only thing I m jealous of is they are talking about a phase 2/3 trial already whereas ENTA is conducting a phase 2 only.